Business Context and Reporting Period
This Form 8-K Current Report was filed by Corbus Pharmaceuticals Holdings, Inc. on April 11, 2016. The filing discloses amendments to existing employment agreements for three executive officers and the execution of a new employment agreement for a newly appointed Chief Medical Officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
Material Changes and Executive Compensation
On April 11, 2016, the Company formalized compensation changes effective January 1, 2016, for the following executives. All agreements extend or establish a term expiring on April 11, 2018:
- Yuval Cohen, Ph.D. (CEO): Annual base salary of $370,000; eligible for an annual bonus targeted up to 50% of base salary.
- Mark Tepper, Ph.D. (President and CSO): Annual base salary of $320,000; eligible for an annual bonus targeted up to 45% of base salary.
- Sean Moran (CFO): Annual base salary of $305,000; eligible for an annual bonus targeted up to 40% of base salary. Includes severance provisions of 12 months' base salary plus COBRA coverage if terminated without cause or for good reason.
- Barbara White, M.D. (CMO): New agreement with an annual base salary of $345,000; eligible for an annual bonus targeted up to 40% of base salary. Includes severance provisions of 12 months' base salary plus COBRA coverage if terminated without cause or for good reason, subject to Section 4999 excise tax reductions.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. The primary contingency noted is the potential reduction of severance payments for Dr. White and Mr. Moran to avoid excise taxes under Internal Revenue Code Section 4999 in the event of a change in control.
Investor Verification Checklist
- Verify the total annual cash compensation cost for the executive team based on the disclosed base salaries and target bonus percentages.
- Review the attached Exhibits 10.1 through 10.4 for full details on non-compete, non-solicitation, and confidentiality provisions.
- Confirm the impact of the "good reason" and "without cause" termination clauses on potential future cash outflows.
- Note that these compensation terms were previously approved by the Compensation Committee and disclosed in a prior Form 8-K filed on January 11, 2016.